Browse drugs

…d due to lack of efficacy. Tolerability was generally good. For atogepant, six patients stopped due to adverse events, most commonly fati…

…imegepant 75 mg) and 6.6% (placebo) of participants.Conclusions Rimegepant 75 mg demonstrated efficacy superior to placebo for acute treat…

…); −2.5 (IQR:(−5.75)-0) for rimegepant and −2 (IQR:(−12)-0) for atogepant. A ≥50% MMDw9–12 reduction was achieved by 25% overall, 25% wit…

…or triptans, respectively, reported treatment optimization. For rimegepant, 95% of physicians and 97% of patients reported satisfaction wi…

…or secondary efficacy endpoints favoured rimegepant vs placebo. Rimegepant was well tolerated.Conclusions Rimegepant 75 mg EOD demonstrate…

…, 0.5]) and lack of efficacy (OR = 0.3 [0.2, 0.4]). Compared to zolmitriptan, rimegepant patients had reduced risk of experiencing all presp…

…seen in subgroup analyses of specific triptans (rizatriptan and sumatriptan) and in chronic migraine patients.Conclusions Patients from the…

…riptyline (89.1%), flunarizine (78.3%), topiramate (76.1%), and zonisamide (50.0%). Prior biologic therapy included three agents in 13.0% …

…al for cardiovascular or cerebrovascular events associated with rimegepant. Routine pharmacovigilance is ongoing, including a Post Authori…

…epant: 5 changed from erenumab, 2 from galcanezumab, and 1 from galcanezumab. There were 11 line changes to eptinezumab: 5 from erenumab, 4 …

…RP antibodies. Treatment: 56 (82.6%) atogepant and nine (13.8%) rimegepant.Response rate: 18 (28.1%) had CR, six (9.4%) presented PR, 28 (…

…9% male; 64.6% received fremanezumab, 24.8% erenumab, 10.6% and galcanezumab; 75.7% were on first-line therapy, 21.7% second-line and 2.7% t…